Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort

Vaccine

Volumn 33, Issue 12, 2015, Pages 1446-1452

  Hmamouchi, Ihsane ^a,b   Winthrop, Kevin ^c   Launay, Odile ^a   Dougados, Maxime ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b MOHAMMED V UNIVERSITY   (Morocco)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Comorbidities; Influenza; Pneumococcus; Rheumatoid arthritis; Vaccine

Indexed keywords

CORTICOSTEROID; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARGENTINA; ARTICLE; AUSTRIA; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; EGYPT; FEMALE; FRANCE; GERMANY; HUMAN; HUNGARY; INFLUENZA; INFLUENZA VACCINATION; ITALY; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALE; MOROCCO; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPAIN; TAIWAN; UNITED KINGDOM; UNITED STATES; URUGUAY; VENEZUELA; CLINICAL TRIAL; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; VACCINATION;

AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; EGYPT; FRANCE; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; JAPAN; MALE; MIDDLE AGED; MOROCCO; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 84924501441     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.065     Document Type: Article

References (42)

1. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.
2. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54:628-634.
3. Naz S.M., Symmons D.P. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21(5):871-883.
4. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
5. Doran M.F., Crowson C.S., Pond G.R., O-Fallon W.M., Gabriel S.E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300.
6. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39:327-346.
7. Avery R.K. Vaccination of the immunosuppressed adult patient with rheumatologic disease. Rheum Dis Clin North Am 1999, 25:567-584.
8. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34:272-279.
9. Mori S., Ueki Y., Akeda Y., et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013, 72(8):1362-1366.
10. Hua C., Barnetche T., Combe B., Morel J. Effect of methotrexate, anti-TNFα and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2013, (Dec). 10.1002/acr.22246.
11. Gluck T. Vaccinate your immunocompromised patients. Rheumatology 2006, 45:9-10.
12. Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012, 21:57-65.
13. Centers for Disease Control and Prevention (CDC) Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2006, 55:1-42.
14. Singh J.A., Furst D.E., Bharat A., et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.
15. van Assen S., Agmon-Levin N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
16. Garrido López B.C., Navarro Compain M.V., Navarro Sarabia F. Vaccines and chemo-prophylaxis in rhemautoid arthritis: is a vaccine calendar necessary?. Reumatol Clin 2011, 7(6):412-416.
17. European Medicines Agency Prevenar 13. Summary of product characteristics 2011.
18. Desai S.P., Turchin A., Szent-Gyorgyi L.E., et al. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. Rheumatology 2011, 50:366-372.
19. Lanternier F., Henegar C., Mouthon L., Blanche P., Guillevin L., Launay O. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 2008, 67:1047.
20. Rahier J., Moutschen M., Van Gompel A., Van Ranst M., Louis E., et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology 2010, 49:1815-1827.
21. Dougados M., Soubrier M., Antunez A., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014, 73:62-68.
22. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
23. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
24. Garrido López B.C., Navarro Compain M.V., Navarro Sarabia F. Vaccines and chemo-prophylaxis in rhemautoid arthritis: is a vaccine calendar necessary?. Reumatol Clin 2001, 7(6):412-416.
25. Pradeep J., Watts R., Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:837-838.
26. Shimazawa R., Ikeda M. The vaccine gap between Japan and the UK. Health Policy Vaccines 2012, 107(2-3):312-317.
27. Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. Vaccine 2011, 29:9459-9466.
28. Commission on the Future of Vaccines in Latin America Strengthening vaccination policies in Latin America 2008, Instituto Carlos Slim de la Salud, D.F., Mexico.
29. Tapia-Conyer R., Betancourt-Cravioto M., Saucedo-Martínez R., Motta-Murguía L., Gallardo-Rincón H. Strengthening vaccination policies in Latin America: an evidence-based approach. Vaccine 2013, 31(37):3826-3833.
30. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010, 59:1102-1106.
31. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61(40):816-819.
32. Papadopoulou D., Sipsas N.V. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int 2014, 34(2):151-163. 10.1007/s00296-013-2907-9.
33. Goëb V., Ardizzone M., Arnaud L., Avouac J., Baillet A., Belot A., et al. Club Rhumatismes et Inflammations (CRI). French Society for Rheumatology. Recommendations for using TNFα antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. Joint Bone Spine 2013 Dec, 80(6):574-581.
34. Hung I.F., Tantawichien T., Tsai Y.H., Patil S., Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis 2013, 17:e364-e373.
35. Centers for Disease Control and Prevention (CDC) Progress in introduction of pneumococcal conjugate vaccine-worldwide, 2000-2012. MMWR Morb Mortal Wkly Rep 2013, 62(Apr (16)):308-311.
36. Isturiz R.E., Luna C.M., Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis 2010, 14:e852-e856.
37. Kawakami K., Ohkusa Y., Kuroki R., et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010, 28:7063-7069.
38. Liao W.H., Lin S.H., Lai C.C., et al. Impact of pneumococcal vaccines on invasive pneumococcal disease in Taiwan. Eur J Clin Microbiol Infect Dis 2010, 29:489-492.
39. Kaddar M., Schmitt S., Makinen M., Milstien J. Global support for new vaccine implementation in middle-income countries. Vaccine 2013, 31:B81-B96.
40. Bridges M.J., Coady D., Kelly C.A., Hamilton J., Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:685.
41. United Kingdom Health Protection Agency. Vaccine uptake guidance and the latest coverage data 〈http://www.hpa.org.uk〉.
42. Balicer Ran D., Cohen Chandra J. Pneumococcal vaccine targeting strategy for older adults: customized risk profiling. Vaccine 2014, 32(8):990-995.